01
Anti-Bribery & HCP Interactions
Speaker programs, advisory boards, samples, and meals — every HCP interaction carries FCPA and Bribery Act risk.
Loading...
Global pharma compliance fines in the last decade
Largest FCPA pharma settlement (Novartis, 2020)
Of pharma enforcement involves anti-bribery violations
Speaker programs, advisory boards, samples, and meals — every HCP interaction carries FCPA and Bribery Act risk.
GCP, informed consent, data integrity, and cross-border trial data transfers under GDPR.
Patient data, pharmacovigilance records, and real-world evidence all fall under GDPR and HIPAA.
Adverse event reporting obligations require trained staff across medical affairs and safety.
Researchers, clinical operations, study coordinators. GxP, GCP, clinical trial ethics, data integrity, informed consent.
Production, quality, validation teams. GMP, deviation management, change control, audit preparation.
Sales reps, medical affairs, marketing. Anti-bribery, fair-market value, transparency reporting, promotional rules.
Regulatory affairs, compliance, board. Pharmacovigilance, AI medical device, audit readiness, board reporting.
Tracks group multiple courses around a single regulation or risk area. Pick one, a few, or build a full programme — each module maps to the article, section, or directive it supports.
FCPA and UK Bribery Act for HCP interactions, speakers, and KOL programs
Data protection for clinical trial data, patient records, and pharmacovigilance
High-risk classification for AI in drug discovery and diagnostics
Good practice regulations covering manufacturing, clinical, and laboratory operations
Reporting channels for compliance violations and safety concerns
Cybersecurity requirements for pharmaceutical manufacturing and R&D